恩格列净用于接受体外循环冠状动脉旁路移植术的2型糖尿病患者:POST-CABGDM随机临床试验
在巴西开展的一项研究者发起的、实用性、单中心、随机、开放标签、结局盲法判定的试验,纳入145例拟行择期体外循环冠状动脉旁路移植术的2型糖尿病患者,随机接受恩格列净25 mg每日一次联合标准治疗(n=71,术前72小时停药)或单纯标准治疗(n=74)。恩格列净组术后7天内急性肾损伤发生率为22.5%,对照组为39.1%(相对危险度0.57,95%置信区间0.34-0.96;P=0.03);两组心房颤动和5型心肌梗死发生率相似,安全性事件无统计学显著差异。作者认为恩格列净与术后急性肾损伤发生率降低相关且不增加安全性事件,这些发现需在更大规模临床试验中确认。
要点
- 恩格列净组术后7天内急性肾损伤发生率为22.5%,对照组为39.1%(相对危险度0.57,95%置信区间0.34-0.96;P=0.03)。
- 两组术后30天心房颤动发生率分别为15.4%和13.5%(相对危险度1.15,95%置信区间0.52-2.53;P=0.73)。
- 两组5型心肌梗死发生率分别为1.4%和4.1%(相对危险度0.35,95%置信区间0.04-3.26;P=0.62),安全性事件无统计学显著差异。
核心结论
- 在2型糖尿病患者中,体外循环冠状动脉旁路移植术前使用恩格列净与术后急性肾损伤发生率降低相关,且未增加安全性事件。
- 作者指出这些发现需在更大规模临床试验中确认。
研究设计与样本
- 研究者发起的、实用性、单中心、随机、开放标签试验,采用结局盲法判定,在巴西开展。
- 共145例拟行择期体外循环冠状动脉旁路移植术的2型糖尿病患者,随机接受恩格列净25 mg每日一次联合标准治疗至少3个月并于术前72小时停药(n=71)或单纯标准治疗(n=74)。
- 主要结局为术后7天内急性肾损伤,采用基于肌酐的标准(急性肾损伤网络、风险-损伤-衰竭-肾功能丧失-终末期肾病、或肾脏病改善全球预后)定义。
主要发现
- 恩格列净组急性肾损伤发生率为22.5%,对照组为39.1%(相对危险度0.57,95%置信区间0.34-0.96;P=0.03)。
- 恩格列净组心房颤动发生率为15.4%,对照组为13.5%(相对危险度1.15,95%置信区间0.52-2.53;P=0.73)。
- 恩格列净组5型心肌梗死发生率为1.4%,对照组为4.1%(相对危险度0.35,95%置信区间0.04-3.26;P=0.62)。
- 两组安全性事件(酮症酸中毒、尿路感染、医院获得性肺炎、伤口感染)无统计学显著差异。
- 共发生3例死亡,均在对照组。
关键数值与推荐
- 主要结局急性肾损伤定义采用基于肌酐的标准:急性肾损伤网络、风险-损伤-衰竭-肾功能丧失-终末期肾病、或肾脏病改善全球预后。
- 恩格列净用法为25 mg每日一次,至少3个月,术前72小时停药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出这些发现需在更大规模临床试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of empagliflozin in patients with type 2 diabetes mellitus (T2DM) undergoing elective on-pump coronary artery bypass grafting (CABG). RESEARCH DESIGN AND METHODS: Investigator-initiated, pragmatic, single-center, randomized, open-label trial with blinded outcome adjudication conducted in Brazil. A total of 145 patients with T2DM scheduled for elective on-pump CABG were randomized to receive empagliflozin 25 mg daily plus standard care (n = 71) for at least 3 months, which was discontinued 72 h before surgery, or to received standard care alone (n = 74). The primary outcome was postoperative acute kidney injury (AKI) within 7 days of surgery, defined by creatinine-based criteria (namely, Acute Kidney Injury Network; Risk, Injury, Failure, Loss of Kidney Function, and End-Stage Kidney Disease; or Kidney Disease: Improving Global Outcomes). Secondary outcomes included 30-day postoperative atrial fibrillation and type 5 myocardial infarction (MI). Safety outcomes were ketoacidosis, urinary tract infection, hospital-acquired pneumonia, and wound infection within 30 days after CABG. RESULTS: AKI occurred in 22.5% of the empagliflozin group vs. 39.1% in the control group (relative risk [RR] 0.57 [95% CI 0.34-0.96]; P = 0.03). Rates of atrial fibrillation (15.4% vs. 13.5%; RR 1.15 [95% CI 0.52-2.53]; P = 0.73) and type 5 MI (1.4% vs. 4.1%; RR 0.35 [95% CI 0.04-3.26]; P = 0.62) were similar between groups. No statistically significant differences between groups were observed for safety events. Three deaths occurred, all in the control group. CONCLUSIONS: Empagliflozin use before on-pump CABG in patients with T2DM was associated with a reduced incidence of postoperative AKI without an increase in safety events. These findings warrant confirmation in larger clinical trials.
引用
- Pitta FG, Lima EG, Tavares CAM, et al. Empagliflozin in Patients With Type 2 Diabetes Undergoing On-Pump CABG: The POST-CABGDM Randomized Clinical Trial. Diabetes Care. 2025. PMID: 40233024. doi:10.2337/dc24-2807
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。